Sunitinib Shows Promise in Metastatic Melanoma Patients
Sunitinib, a tyrosine kinase inhibitor, has been approved by the FDA for the treatment of kidney cancer and stromal gastrointestinal cancer, but its effectiveness in melanoma was unknown until this study.